January 2023

Read up on essential news

We want to keep you informed. Here are a few important news items and reminders for you this month.

Revenue codes that require HCPCS code

This article applies to both commercial and Medicare members.

Reminder: We require that certain revenue codes be submitted with a procedure code (CPT/HCPCS) for bill types 12X, 13X, 14X, 74X, 75X and 76X.

A revenue code is a summary billing code that indicates the type of service provided and where it was performed. Revenue codes also identify ancillary charges and/or specific accommodations.

Changes to our National Precertification List (NPL)

This update applies to both our commercial and Medicare members.

The following new-to-market drugs require precertification:

- **Stimufend® (pegfilgrastim-fpgk)** — precertification is required starting January 1, 2023. This drug is part of the Granulocyte Colony-Stimulating Factor drug category.
- **Rolvedon™ (eflapegrastim-xnst)** — precertification is required starting January 1, 2023. This drug is part of the Granulocyte Colony-Stimulating Factor drug category.
- **Vegzelma® (bevacizumab-adcd)** — precertification is required starting January 1, 2023.

You can always find these policies on our Availity® provider portal.

Access Availity

Quick reminder: You can use our Code Edit Lookup tools on Availity®.

Just go to Payer Space > Applications > Code Edit Lookup Tools. And keep your Aetna® provider ID number handy to access them.
• Pedmark® (sodium thiosulfate) — precertification is required starting January 10, 2023.
• Tecvayli™ (teclistamab-cqv) — precertification is required starting January 10, 2023.
• Zynteglo® (betibeglogene autotemcel) — precertification is required starting January 1, 2023.
• Skysona®/Lenti-D (elivaldogene autotemcel or eli-cel) — precertification is required starting January 1, 2023.
• Xenpozyme® (olipudase alfa-rpcp) — precertification is required for both the drug and site of care starting January 1, 2023. This drug is part of the Enzyme Replacement drug category.
• Spevigo® (spesolimab-sbzo) — precertification is required starting January 1, 2023. This drug is part of the Immunologic Agents drug category.
• Cimerli™ (ranibizumab-eqrn) — precertification is required starting January 5, 2023. This drug is part of the Ophthalmic Medical Injectables drug category.

**Submitting precertification requests**

Be sure to submit precertification requests at least two weeks in advance. To save time, request precertification online. Doing so is fast, secure and simple.

You can submit most requests online through our [Availity provider portal].* Or you can use your practice’s Electronic Medical Record (EMR) system if it’s set up for electronic precertification requests. Use our “Search by CPT® code” search function on our Precertification Lists page to find out if the code requires precertification.**

Learn more about precertification.

Are you asking for precertification on a specialty drug for a commercial or Medicare member? Then submit your request through Novologix®, also available on Availity®. Not registered for Availity? Go to Availity to register and learn more.

*Availity is available only to providers in the U.S. and its territories.

**CPT® is a registered trademark of the American Medical Association.
Aetna is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

Help/contact us:
If you have any questions, please contact us.

Want to stop receiving messages like these through email? Unsubscribe at any time.

We are located at 151 Farmington Avenue, Hartford, CT 06156.

Privacy Statement | Terms of Use | Privacy Information

©2023 Aetna Inc.
1701454-01-01